Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization.

Array-comparative genomic hybridization (a-CGH) is a molecular cytogenetic technique for detection of multiple chromosomal abnormalities in genomic DNA samples. Using an a-CGH with 287 probes, we examined 14 cases of breast infiltrating ductal carcinoma (IDCA) that had previously been classified by fluorescent in situ hybridization (FISH) as either human epidermal growth factor receptor-2 positive (HER2+) or HER2- and analyzed the data by hierarchical, K-means, and principal component analyses. The aim of the study was to identify the genetic abnormalities that are present in breast IDCAs and determine if the global status of 287 cytogenetic locations could be used as a more objective method for breast IDCA classification. Concordance between FISH and a-CGH at the HER2 locus was 78.6% (11/14). In general, a-CGH detected more abnormalities in HER2+ cases. In HER 2+ cases, chromosomes 1, 2, 3, 7, 9, 17, and 20 had more regions that showed statistically significant (P < or = 0.01) changes in DNA copy number. Among all the aberrant cytogenetic locations detected, 20q13, 7p12.3 approximately p12.1, and 17q23.2 approximately q25.3, which contain among others, genes for TNFRSF6B, EGFR, and TK1 showed statistically significant gains (P < or = 0.01) in 83, 66.7, and 50% of the HER2+ IDCA cases, respectively. Chromosome location 8q24.12 approximately q24.13 was the only region that showed consistent amplification in approximately 50% of the HER2- cases. Unsupervised hierarchical and K-means cluster analyses and principal component analysis using the DNA copy number status of 287 cytogenetic locations or the 177 cytogenetic locations that showed statistically significant differences revealed a cluster consisting of mainly HER2- IDCA cases. Even though this study demonstrates the usefulness of a-CGH in the rapid identification of aberrant DNA regions in tumor samples, we conclude that an array-CGH with more than 287 probes will be needed for a more precise mapping of DNA aberrations at the global level.

[1]  G. Hortobagyi,et al.  HER2/neu in the management of invasive breast cancer. , 2002, Journal of the American College of Surgeons.

[2]  T. Kawarabayashi,et al.  Establishment of a new human malignant fibrous histiocytoma cell line, FU-MFH-1: cytogenetic characterization by comparative genomic hybridization and fluorescence in situ hybridization. , 2003, Cancer genetics and cytogenetics.

[3]  A. Lewiński,et al.  Expression of genes for certain enzymes of pyrimidine and purine salvage pathway in peripheral blood leukocytes collected from patients with Graves' or Hashimoto's disease , 2003, Journal of cellular biochemistry.

[4]  J. Reis-Filho,et al.  c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant? , 2003, Breast Cancer Research.

[5]  T. Shuin,et al.  Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. , 2002, Cancer genetics and cytogenetics.

[6]  R. Bohle,et al.  HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. , 2003, Clinical chemistry.

[7]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J Khan,et al.  Detection of gene amplification by genomic hybridization to cDNA microarrays. , 2000, Cancer research.

[9]  H. Moch,et al.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.

[10]  J. Siegfried,et al.  Combined chromosome microdissection and comparative genomic hybridization detect multiple sites of amplified DNA in a human lung carcinoma cell line , 1997, Genes, chromosomes & cancer.

[11]  X. Guan,et al.  Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. , 2003, Cancer genetics and cytogenetics.

[12]  P. Moore,et al.  Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients , 2003, International journal of cancer.

[13]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[14]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays , 1999, Nature Genetics.

[15]  M. Urioste,et al.  Array comparative genomic hybridization analysis of myelodysplastic syndromes with complex karyotypes. A technical evaluation. , 2003, Cancer genetics and cytogenetics.

[16]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Döhner,et al.  Matrix‐based comparative genomic hybridization: Biochips to screen for genomic imbalances , 1997, Genes, chromosomes & cancer.

[18]  M. Dowsett,et al.  Assessment of HER2 status in breast cancer: why, when and how? , 2000, European journal of cancer.

[19]  C. Ihm,et al.  Detection of genetic alterations in bladder tumors by comparative genomic hybridization and cytogenetic analysis. , 1999, Cancer genetics and cytogenetics.

[20]  S. Somiari,et al.  Functional relationship and gene ontology classification of breast cancer biomarkers. , 2003, The International journal of biological markers.

[21]  T. Fornander,et al.  The Clinical Significance of Thymidine Kinase 1 Measurement in Serum of Breast Cancer Patients Using Anti-TK1 Antibody , 2000, The International journal of biological markers.

[22]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[23]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy-number changes using cDNA microarrays , 1999, Nature Genetics.

[24]  J Piper,et al.  Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors , 1994, Genes, chromosomes & cancer.

[25]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Calvo,et al.  ErbB2 and EGFR are downmodulated during the differentiation of 3T3‐L1 preadipocytes , 2003, Journal of cellular biochemistry.

[27]  M. Bui,et al.  Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. , 2000, Annals of clinical and laboratory science.

[28]  C. Fuster,et al.  Analysis of kidney tumors by comparative genomic hybridization and conventional cytogenetics. , 2002, Cancer genetics and cytogenetics.

[29]  S. Galiègue,et al.  Mutation analysis in the coding sequence of thymidine kinase 1 in breast and colorectal cancer. , 2003, The International journal of biological markers.

[30]  H. Linardou,et al.  New Molecular Targets and Therapeutic Strategies against Cancer , 1993, The International journal of biological markers.

[31]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[32]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[33]  G. Houge,et al.  Usefulness of high-resolution comparative genomic hybridization (CGH) for detecting and characterizing constitutional chromosome abnormalities. , 2002, American journal of medical genetics.

[34]  J. Cigudosa,et al.  Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  Y. Tagawa,et al.  Comparative genomic hybridization analysis detected frequent overrepresentation of chromosome 3q in squamous cell carcinoma of the lung. , 2002, Lung cancer.

[36]  K. Reddy,et al.  Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. , 2003, Molecular cancer research : MCR.